Sir Patrick Vallance

Sir Patrick Vallance
Name	Sir Patrick Vallance
Birth date	1960
Birth place	Swansea
Alma mater	University College London, University of Cambridge
Occupation	physician, clinical pharmacologist, biotechnology, academic, science policy
Known for	Chief Scientific Adviser (United Kingdom), COVID-19 pandemic in the United Kingdom

Sir Patrick Vallance is a British physician, clinical pharmacologist, and biomedical researcher who served as the United Kingdom's Chief Scientific Adviser (United Kingdom) and head of the Government Office for Science from 2018 to 2023. He held senior executive roles in the biopharmaceutical industry and contributed to translational medicine, drug development, and science policy during intersections with public health, National Health Service (England), and global health institutions. Vallance's tenure overlapped with major events including the COVID-19 pandemic in the United Kingdom, debates on vaccine development, and interactions with parliamentary bodies such as the Science and Technology Committee.

Early life and education

Vallance was born in Swansea and educated at regional schools before attending University College London where he studied medicine. He completed clinical training and research at the University of Cambridge and gained a foundation in clinical pharmacology and cardiovascular medicine through posts at teaching hospitals affiliated with the National Health Service (England). During his early career he engaged with academic groups linked to the Medical Research Council and the Wellcome Trust.

Academic and pharmaceutical career

Vallance combined academic appointments with roles in the biopharmaceutical sector, moving between University of Cambridge research units and industry. He worked on mechanisms of nitric oxide and vascular biology, publishing with collaborators from institutions such as the Royal Society fellows and researchers associated with Imperial College London and King's College London. In industry he held senior positions at GlaxoSmithKline and later became President of Research and Development at GlaxoSmithKline plc before joining the biotechnology firm SV Health Investors and advising venture capital and pharmaceutical boards including those linked to AstraZeneca and multinational partnerships. His career connected him to regulatory and translational networks including the European Medicines Agency, Food and Drug Administration, and professional bodies like the Royal College of Physicians.

Government service and role as Chief Scientific Adviser

Appointed as Chief Scientific Adviser (United Kingdom) in 2018, Vallance led the Government Office for Science and provided scientific counsel to ministers across departments including Cabinet Office, Department of Health and Social Care, and No. 10 Downing Street. He coordinated expert advisory inputs from committees such as SAGE (scientific advisory group), the National Institute for Health and Care Research, and the Chief Medical Officer (United Kingdom), engaging with international counterparts at the World Health Organization and national science advisers from countries including United States, Germany, and France. Vallance's remit involved strategic planning on life sciences industrial strategy intersecting with initiatives like the Industrial Strategy and partnerships with bodies such as the Wellcome Trust and UK Research and Innovation.

COVID-19 pandemic involvement

During the COVID-19 pandemic in the United Kingdom, Vallance was a prominent figure in public briefings alongside the Prime Minister of the United Kingdom, the Chief Medical Officer (United Kingdom), and the Secretary of State for Health and Social Care. He addressed issues including non-pharmaceutical interventions, modelling from groups like the Imperial College COVID-19 Response Team, and discussions about herd immunity, testing strategies with agencies such as Public Health England, and vaccine development efforts involving Oxford University and partners like AstraZeneca. Vallance gave evidence to parliamentary inquiries including the Health and Social Care Committee and the Science and Technology Committee on topics of modelling, pandemic preparedness, and the timeline of scientific advice. He was associated with coordination between the UK government and research consortia such as the COVID-19 Genomics UK Consortium and initiatives for accelerated regulatory pathways with the Medicines and Healthcare products Regulatory Agency.

Honours and awards

Vallance has received honours reflecting his contributions to medicine, science, and public service, including fellowship of the Royal Society and fellowships at the Academy of Medical Sciences and the Royal College of Physicians. He was knighted in the 2021 Birthday Honours for services to science and public health, and has been recognised by industry awards and academic lecture appointments at institutions like the Royal Institution and the London School of Hygiene & Tropical Medicine.

Personal life and interests

Vallance has family ties in Wales and maintains professional interests in translational biomedicine, pharmaceutical innovation, and science advisory systems. Outside his official roles he has engaged with charities and trusts connected to medical research funding, and has spoken at events hosted by institutions including the Royal Society of Medicine, the Keble College, Oxford lecture series, and international forums such as the G7 summit science sessions.

Category:British physicians Category:Living people Category:Chief Scientific Advisers (United Kingdom)